Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IRIX's Cash to Debt is ranked higher than
87% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. IRIX: No Debt )
IRIX' s 10-Year Cash to Debt Range
Min: 0.38   Max: No Debt
Current: No Debt

Equity to Asset 0.79
IRIX's Equity to Asset is ranked higher than
83% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. IRIX: 0.79 )
IRIX' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.94
Current: 0.79

0.4
0.94
Interest Coverage 7.10
IRIX's Interest Coverage is ranked lower than
53% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. IRIX: 7.10 )
IRIX' s 10-Year Interest Coverage Range
Min: 6.53   Max: 9999.99
Current: 7.1

6.53
9999.99
F-Score: 7
Z-Score: 8.82
M-Score: -2.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.19
IRIX's Operating margin (%) is ranked higher than
73% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. IRIX: 5.19 )
IRIX' s 10-Year Operating margin (%) Range
Min: -43.43   Max: 15.91
Current: 5.19

-43.43
15.91
Net-margin (%) 4.05
IRIX's Net-margin (%) is ranked higher than
74% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. IRIX: 4.05 )
IRIX' s 10-Year Net-margin (%) Range
Min: -40.11   Max: 11.6
Current: 4.05

-40.11
11.6
ROE (%) 6.54
IRIX's ROE (%) is ranked higher than
76% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. IRIX: 6.54 )
IRIX' s 10-Year ROE (%) Range
Min: -87.4   Max: 19.31
Current: 6.54

-87.4
19.31
ROA (%) 5.15
IRIX's ROA (%) is ranked higher than
81% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. IRIX: 5.15 )
IRIX' s 10-Year ROA (%) Range
Min: -51.3   Max: 10.59
Current: 5.15

-51.3
10.59
ROC (Joel Greenblatt) (%) 18.65
IRIX's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. IRIX: 18.65 )
IRIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -207.6   Max: 34.19
Current: 18.65

-207.6
34.19
Revenue Growth (%) -4.20
IRIX's Revenue Growth (%) is ranked higher than
61% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. IRIX: -4.20 )
IRIX' s 10-Year Revenue Growth (%) Range
Min: -16.2   Max: 25.5
Current: -4.2

-16.2
25.5
EBITDA Growth (%) -8.90
IRIX's EBITDA Growth (%) is ranked higher than
67% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. IRIX: -8.90 )
IRIX' s 10-Year EBITDA Growth (%) Range
Min: -54.3   Max: 178.1
Current: -8.9

-54.3
178.1
EPS Growth (%) 11.20
IRIX's EPS Growth (%) is ranked higher than
82% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. IRIX: 11.20 )
IRIX' s 10-Year EPS Growth (%) Range
Min: -54.3   Max: 255.2
Current: 11.2

-54.3
255.2
» IRIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IRIX Guru Trades in Q4 2013

Jim Simons 161,100 sh (+43.84%)
» More
Q1 2014

IRIX Guru Trades in Q1 2014

Jim Simons 170,000 sh (+5.52%)
» More
Q2 2014

IRIX Guru Trades in Q2 2014

Jim Simons 187,600 sh (+10.35%)
» More
Q3 2014

IRIX Guru Trades in Q3 2014

Jim Simons 202,500 sh (+7.94%)
» More
» Details

Insider Trades

Latest Guru Trades with IRIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.10
IRIX's P/E(ttm) is ranked higher than
77% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. IRIX: 49.10 )
IRIX' s 10-Year P/E(ttm) Range
Min: 8.88   Max: 220.41
Current: 49.1

8.88
220.41
P/B 3.20
IRIX's P/B is ranked higher than
73% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. IRIX: 3.20 )
IRIX' s 10-Year P/B Range
Min: 0.41   Max: 4.1
Current: 3.2

0.41
4.1
P/S 2.10
IRIX's P/S is ranked higher than
77% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. IRIX: 2.10 )
IRIX' s 10-Year P/S Range
Min: 0.11   Max: 2.83
Current: 2.1

0.11
2.83
PFCF 59.30
IRIX's PFCF is ranked higher than
83% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 59.30 )
IRIX' s 10-Year PFCF Range
Min: 0.3   Max: 355.5
Current: 59.3

0.3
355.5
EV-to-EBIT 31.81
IRIX's EV-to-EBIT is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. IRIX: 31.81 )
IRIX' s 10-Year EV-to-EBIT Range
Min: -982.5   Max: 1115.6
Current: 31.81

-982.5
1115.6
Shiller P/E 80.00
IRIX's Shiller P/E is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 80.00 )
IRIX' s 10-Year Shiller P/E Range
Min: 36.71   Max: 1080
Current: 80

36.71
1080
Current Ratio 4.72
IRIX's Current Ratio is ranked higher than
83% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. IRIX: 4.72 )
IRIX' s 10-Year Current Ratio Range
Min: 1.02   Max: 13.85
Current: 4.72

1.02
13.85
Quick Ratio 3.25
IRIX's Quick Ratio is ranked higher than
80% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. IRIX: 3.25 )
IRIX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 12.25
Current: 3.25

0.62
12.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.40
IRIX's Price/Net Cash is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 13.40 )
IRIX' s 10-Year Price/Net Cash Range
Min: 2.53   Max: 500
Current: 13.4

2.53
500
Price/Net Current Asset Value 4.90
IRIX's Price/Net Current Asset Value is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 4.90 )
IRIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 9.44
Current: 4.9

1.06
9.44
Price/Tangible Book 3.30
IRIX's Price/Tangible Book is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. IRIX: 3.30 )
IRIX' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 26.67
Current: 3.3

0.66
26.67
Price/DCF (Projected) 2.00
IRIX's Price/DCF (Projected) is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 2.00 )
IRIX' s 10-Year Price/DCF (Projected) Range
Min: 0.74   Max: 19.46
Current: 2

0.74
19.46
Price/Median PS Value 1.70
IRIX's Price/Median PS Value is ranked higher than
62% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. IRIX: 1.70 )
IRIX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 6.47
Current: 1.7

0.13
6.47
Price/Graham Number 2.70
IRIX's Price/Graham Number is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IRIX: 2.70 )
IRIX' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 4.41
Current: 2.7

0.8
4.41
Earnings Yield (Greenblatt) 3.10
IRIX's Earnings Yield (Greenblatt) is ranked higher than
76% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. IRIX: 3.10 )
IRIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 11.7
Current: 3.1

0.1
11.7
Forward Rate of Return (Yacktman) -9.79
IRIX's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. IRIX: -9.79 )
IRIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -34.3   Max: 22.5
Current: -9.79

-34.3
22.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IX4.Germany
Iridex Corp was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the Company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. Its ophthalmology products consist of laser console, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration. In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a consumable single use intraocular laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company has been issued 26 United States patents and 17 foreign patents. It is subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.
» More Articles for IRIX

Headlines

Articles On GuruFocus.com
IRIDEX Corp. Reports Operating Results (10-Q) Nov 04 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 05 2010 
IRIDEX Corp. Reports Operating Results (10-Q) May 06 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Nov 12 2009 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 13 2009 
IRIDEX Reports Second Quarter 2009 Financial Results Aug 13 2009 
IRIDEX Corp. Reports Operating Results (10-Q) May 15 2009 
IRIDEX Corp. (IRIX) CFO James H Mackaness buys 2,000 Shares Mar 13 2009 

More From Other Websites
IRIDEX Secures Large Tender from Government of Zambia for Ophthalmology Laser Equipment Nov 19 2014
IRIDEX Secures Large Tender from Government of Zambia for Ophthalmology Laser Equipment Nov 19 2014
10-Q for IRIDEX Corp. Nov 05 2014
IRIDEX CORP Files SEC form 10-Q, Quarterly Report Nov 03 2014
IRIDEX Corp Earnings Call scheduled for 5:00 pm ET today Oct 30 2014
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
IRIDEX Reports 2014 Third Quarter, Nine-Month Results Oct 30 2014
Q3 2014 IRIDEX Corp Earnings Release - After Market Close Oct 30 2014
IRIDEX Announces Third Quarter 2014 Conference Call and Release Date Oct 23 2014
IRIDEX Announces Third Quarter 2014 Conference Call and Release Date Oct 23 2014
IRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology Oct 17 2014
IRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology Oct 17 2014
IRIDEX Expands Retinal Portfolio Oct 14 2014
IRIDEX Granted U.S. Patent for Disposable MicroPulse® Delivery Device for the Non-invasive... Oct 07 2014
IRIDEX Reports Strong Attendance at European Workshop for its Proprietary MicroPulse® Laser Therapy... Oct 01 2014
IRIDEX to Present at Robert W. Baird 2014 Health Care Conference Aug 27 2014
IRIDEX CORP Financials Aug 12 2014
Director Garrett A. Garrettson, Ph.D. to Step Down After Decade-Long Service Aug 07 2014
IRIDEX to Present at 2014 Wedbush Life Sciences Management Access Conference Aug 05 2014
IRIDEX CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 04 2014
IRIDEX Earnings Call scheduled for 5:00 pm ET today Jul 31 2014
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
IRIDEX Reports 2014 Second Quarter, Six-Month Results Jul 31 2014
IRIDEX Announces Second Quarter 2014 Conference Call and Release Date Jul 24 2014
IRIDEX Announces New Multi-Center Study Data Demonstrates Safety, Durability of Proprietary... May 22 2014
IRIDEX Reports 2013 Fourth Quarter Results Feb 27 2014
IRIDEX Announces Fourth Quarter and Full Year 2013 Conference Call and Release Date Feb 20 2014
IRIDEX Announces Preliminary Unaudited Revenues For 2013 Fourth Quarter and Year End Jan 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK